<html><style> .textDiv { width: 900px; border: 25px solid #58D3F7; padding: 25px; margin: 25px; font-family: 'Arial', Times, serif; font-size: 16px; text-align: justify;} .title { margin: 50px 50px 50px 25px; font-family: 'Arial', Times, serif; font-size: 40px; font-weight: bold; color:  #58D3F7; text-align: left;} </style><head></head><body><div class='title'>extractUncertainty_Unspecified</div><div class='textDiv'><span style='background-color: #A9E2F3'>Valeritas on deck for IPO - Valeritas (Pending:VLRX) | Seeking Alpha Mar 12 2015, 13:42 ET | About: Valeritas (VLRX) | By: Douglas W. House , SA News Editor Bridgewater, NJ-based Valeritas (Pending: VLRX ) is set for its IPO of 5M shares of common stock at $14 - 16.</span>The commercial stage medical device firm focuses on products for people with type 2 diabetes.Its sole offering is the V-Go Disposable Insulin Delivery Device.The product is placed (adhered) on the skin where it delivers insulin at a continuous basal (background) rate over a 24-hour period and on demand around mealtime (prandial).It is the only FDA-approved mechanical basal-bolus delivery device in the U.S.The company began hiring sales reps in H2 2012 and now has 63 covered territories.It estimates that ~13,000 patients were using V-Go as of the end of 2014.The company is working on a next-generation V-Go that is pre-filled with insulin, thereby eliminating the device-filling process required by the current version.2014 financial performance ($M):ï¿½Revenues: 13.5 (+118.9%); Gross Margin: (4.3) (+64.2%); Operating Expenses: 54.8 (-24.7%); Net Loss: (6.5) (-135.4%); CF Ops: (48.0) (+43.7%).ETF Performance: View ETF performance across key asset classes and investing themes</div></body></html>